Subscriber Authentication Point
lvrea
Home All issues Volume 25 / No 5 (Septembre 2016) Méd. Intensive Réa, 25 5 (2016) 491-505 References
Free Access
Issue
Méd. Intensive Réa
Volume 25, Number 5, Septembre 2016
Médecine d'urgence-Neuroréanimation
Page(s) 491 - 505
Section Mise Au Point / Update
DOI https://doi.org/10.1007/s13546-016-1223-2
Published online 23 July 2016
  • Ferenci P, Lockwood A, Mullen K, et al (2002) Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35:716–21 [CrossRef] [PubMed] [Google Scholar]
  • Streetz KL, Tacke F, Koch A, et al (2013) [Acute liver failure. Diagnosis and therapy]. Med Klin Intensivmed Notfmed 108:639–45 [PubMed] [Google Scholar]
  • Reuben A, Tillman H, Fontana RJ, et al (2016) Outcomes in Adults With Acute Liver Failure Between 1998 and 2013: An Observational Cohort Study. Ann Intern Med. 11:724–32 [Google Scholar]
  • Bustamante J, Rimola A, Ventura PJ, et al (1999) Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 30:890–5 [CrossRef] [PubMed] [Google Scholar]
  • Orman ES, Perkins A, Ghabril M, et al (2015) The confusion assessment method for the intensive care unit in patients with cirrhosis. Metab Brain Dis 30:1063–71 [PubMed] [Google Scholar]
  • Levesque E, Hoti E, Azoulay D, et al (2012) Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol 56:95–102 [CrossRef] [PubMed] [Google Scholar]
  • Joshi D, O’Grady J, Patel A, et al (2014) Cerebral oedema is rare in acute-on-chronic liver failure patients presenting with high-grade hepatic encephalopathy. Liver Int 34:362–6 [PubMed] [Google Scholar]
  • Lockwood AH, McDonald JM, Reiman RE, et al (1979) The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clin Invest 63:449–60 [PubMed] [Google Scholar]
  • Drolz A, Jager B, Wewalka M, et al (2013) Clinical impact of arterial ammonia levels in ICU patients with different liver diseases. Intensive Care Med 39:1227–37 [CrossRef] [PubMed] [Google Scholar]
  • Watanabe A, Higashi T, Shiota T, et al (1983) Alterations in neutral amino acid transport across the blood-brain barrier in hepatic failure. Res Exp Med (Berl) 183:11–8 [CrossRef] [PubMed] [Google Scholar]
  • Palomero-Gallagher N, Zilles K (2013) Neurotransmitter receptor alterations in hepatic encephalopathy: a review. Arch Biochem Biophys 536:109–21 [CrossRef] [PubMed] [Google Scholar]
  • Rama Rao KV, Norenberg MD (2014) Glutamine in the pathogenesis of hepatic encephalopathy: the trojan horse hypothesis revisited. Neurochem Res 39:593–8 [CrossRef] [PubMed] [Google Scholar]
  • Shawcross DL, Davies NA, Williams R, et al (2004) Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. Journal of Hepatology 40:247–54 [CrossRef] [PubMed] [Google Scholar]
  • Shawcross DL, Wright G, Olde Damink SW, et al (2007) Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 22:125–38 [PubMed] [Google Scholar]
  • Coltart I, Tranah TH, Shawcross DL (2013) Inflammation and hepatic encephalopathy. Arch Biochem Biophys 536:189–96 [CrossRef] [PubMed] [Google Scholar]
  • Albillos A, Lario M, Alvarez-Mon M (2014) Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol 61:1385–96 [CrossRef] [PubMed] [Google Scholar]
  • Watanabe A, Shiota T, Okita M, et al (1983) Effect of a branched chain amino acid-enriched nutritional product on the pathophysiology of the liver and nutritional state of patients with liver cirrhosis. Acta Med Okayama 37:321–33 [Google Scholar]
  • Nguyen JH, Yamamoto S, Steers J, et al (2006) Matrix metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic failure mice. J Hepatol 44:1105–14 [CrossRef] [PubMed] [Google Scholar]
  • Weiss N, Junot C, Rudler M, et al (2016) Hepatic versus drug-induced encephalopathy in cirrhotic patients? Liver Int [in press] [Google Scholar]
  • Quinn M, McMillin M, Galindo C, et al (2014) Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. Dig Liver Dis 46:527–34 [CrossRef] [PubMed] [Google Scholar]
  • Prabhakar S, Bhatia R (2003) Management of agitation and convulsions in hepatic encephalopathy. Indian J Gastroenterol 22 Suppl 2:S54–8 [PubMed] [Google Scholar]
  • Sawhney R, Holland-Fischer P, Rosselli M, et al (2016) Role of ammonia, inflammation and cerebral oxygenation in brain dysfunction of acute on chronic liver failure patients. Liver Transpl. 22:732–42 [CrossRef] [PubMed] [Google Scholar]
  • Mouri S, Tripon S, Rudler M, et al (2015) FOUR score, a reliable score for assessing overt hepatic encephalopathy in cirrhotic patients. Neurocrit Care 22:251–7 [PubMed] [Google Scholar]
  • Cadranel JF, Lebiez E, Di Martino V, et al (2001) Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? Am J Gastroenterol 96:515–8 [Google Scholar]
  • Vilstrup H, Amodio P, Bajaj J, et al (2014) Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60:715–35 [CrossRef] [PubMed] [Google Scholar]
  • Strauss E, da Costa MF (1998) The importance of bacterial infections as precipating factors of chronic hepatic encephalopathy in cirrhosis. Hepatogastroenterology 45:900–4 [PubMed] [Google Scholar]
  • Conn HO (1969) A rational program for the management of hepatic coma. Gastroenterology 57:715–23 [PubMed] [Google Scholar]
  • Weiss N, Mutlu G, Essardy F, et al (2009) [The French version of the FOUR score: A new coma score]. Rev Neurol (Paris) 165:796–802 [CrossRef] [PubMed] [Google Scholar]
  • Schiff S, Casa M, Di Caro V, et al (2016) A low-cost, user-friendly electroencephalographic recording system for the assessment of hepatic encephalopathy. Hepatology 63:1651–9 [CrossRef] [PubMed] [Google Scholar]
  • Amodio P, Montagnese S (2015) Clinical neurophysiology of hepatic encephalopathy. J Clin Exp Hepatol 5:S60–8 [PubMed] [Google Scholar]
  • Parsons-Smith BG, Summerskill WH, Dawson AM, et al (1957) The electroencephalograph in liver disease. Lancet 273:867–71 [CrossRef] [PubMed] [Google Scholar]
  • Marchetti P, D’Avanzo C, Orsato R, et al (2011) Electroencephalography in patients with cirrhosis. Gastroenterology 141:1680-9 e1–2 [Google Scholar]
  • Lai CH, Cheng PY, Chen YY (2011) Liver cirrhosis and risk of intracerebral hemorrhage: a 9-year follow-up study. Stroke 42:2615–7 [PubMed] [Google Scholar]
  • Chavarria L, Cordoba J (2014) Magnetic resonance of the brain in chronic and acute liver failure. Metab Brain Dis 29:937–44 [PubMed] [Google Scholar]
  • Alonso J, Cordoba J, Rovira A (2014) Brain magnetic resonance in hepatic encephalopathy. Semin Ultrasound CT MR 35:136–52 [CrossRef] [PubMed] [Google Scholar]
  • Als-Nielsen B, Gluud LL, Gluud C (2004) Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 328:1046 [CrossRef] [PubMed] [Google Scholar]
  • Sharma P, Agrawal A, Sharma BC, et al (2011) Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 26:996–1003 [CrossRef] [PubMed] [Google Scholar]
  • American Association for the Study of Liver D, European Association for the Study of the L (2014) Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 61:642–59 [CrossRef] [PubMed] [Google Scholar]
  • Blanc P, Daures JP, Rouillon JM, et al (1992) Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 15:222–8 [CrossRef] [PubMed] [Google Scholar]
  • Cutler T, Mints G (2015) Lactulose vs Polyethylene Glycol for Treatment of Hepatic Encephalopathy. JAMA Intern Med 175:867–8 [CrossRef] [PubMed] [Google Scholar]
  • Patidar KR, Bajaj JS (2013) Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis 28:307–12 [PubMed] [Google Scholar]
  • Kimer N, Krag A, Gluud LL (2014) Letter: the effects of rifaximin in hepatic encephalopathy--authors’ reply. Aliment Pharmacol Ther 40:858–9 [PubMed] [Google Scholar]
  • Ponziani FR, Gerardi V, Pecere S, et al (2015) Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 21:12322–33 [CrossRef] [PubMed] [Google Scholar]
  • Ponziani FR, Scaldaferri F, Petito V, et al (2016) The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. Dig Dis 34:269–78 [PubMed] [Google Scholar]
  • Bass NM, Mullen KD, Sanyal A, et al (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362:1071–81 [CrossRef] [PubMed] [Google Scholar]
  • Sharma BC, Sharma P, Lunia MK, et al (2013) A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 108:1458–63 [Google Scholar]
  • Bajaj JS, Barrett AC, Bortey E, et al (2015) Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. Aliment Pharmacol Ther 41:39–45 [PubMed] [Google Scholar]
  • Sanyal A, Younossi ZM, Bass NM, et al (2011) Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther 34:853–61 [PubMed] [Google Scholar]
  • Mullen KD, Sanyal AJ, Bass NM, et al (2014) Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 12:1390–7 e2 [CrossRef] [PubMed] [Google Scholar]
  • Bajaj JS, Riggio O (2010) Drug therapy: rifaximin. Hepatology 52:1484–8 [CrossRef] [PubMed] [Google Scholar]
  • De Leo C, Eftimiadi C, Schito GC (1986) Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 12:979–81 [PubMed] [Google Scholar]
  • Neff GW, Jones M, Jonas M, et al (2013) Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis. J Clin Gastroenterol 47:188–92 [CrossRef] [PubMed] [Google Scholar]
  • Rockey DC, Vierling JM, Mantry P, et al (2014) Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 59:1073–83 [CrossRef] [PubMed] [Google Scholar]
  • Tapper EB, Jiang ZG, Patwardhan VR (2015) Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. Mayo Clin Proc 90:646–58 [PubMed] [Google Scholar]
  • Kao D, Roach B, Park H, et al (2016) Fecal microbiota transplantation in the management of hepatic encephalopathy. Hepatology 63:339–40 [CrossRef] [PubMed] [Google Scholar]
  • Cordoba J, Lopez-Hellin J, Planas M, et al (2004) Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 41:38–43 [CrossRef] [PubMed] [Google Scholar]
  • Lefrant JY, Hurel D, Cano NJ, et al (2014) [Guidelines for nutrition support in critically ill patient]. Ann Fr Anesth Reanim 33:202–18 [Google Scholar]
  • Merli M, Riggio O (2009) Dietary and nutritional indications in hepatic encephalopathy. Metab Brain Dis 24:211–21 [PubMed] [Google Scholar]
  • Les I, Doval E, Garcia-Martinez R, et al (2011) Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol 106:1081–8 [Google Scholar]
  • Als-Nielsen B, Gluud LL, Gluud C (2004) Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database Syst Rev:CD002798 [PubMed] [Google Scholar]
  • Romero-Gomez M (2010) Pharmacotherapy of hepatic encephalopathy in cirrhosis. Expert Opin Pharmacother 11:1317–27 [PubMed] [Google Scholar]
  • Laleman W, Simon-Talero M, Maleux G, et al (2013) Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 57:2448–57 [CrossRef] [PubMed] [Google Scholar]
  • Jalan R, Kapoor D (2004) Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci (Lond) 106:467–74 [CrossRef] [PubMed] [Google Scholar]
  • Simon-Talero M, Garcia-Martinez R, Torrens M, et al (2013) Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol 59:1184–92 [CrossRef] [PubMed] [Google Scholar]
  • Hassanein TI, Tofteng F, Brown RS Jr, et al (2007) Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 46:1853–62 [CrossRef] [PubMed] [Google Scholar]
  • Saliba F, Camus C, Durand F, et al (2013) Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med 159:522–31 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.